Anti-inflammatory effect via natural tear components

Anti-inflammatory effect via natural tear components" is **not a specific molecule, receptor, or canonical therapeutic target**. Instead, it refers to the collective anti-inflammatory actions of various natural constituents found in human tears. These include proteins and peptides such as lactoferrin, lysozyme, defensins, mucins, clusterin, galectin, and lipids[1][3][6]. These components contribute to ocular surface homeostasis by providing antimicrobial defense and modulating inflammation. In dry eye disease and related ocular conditions characterized by inflammation and tear film instability[2][3], the levels or activity of these natural anti-inflammatory factors may be reduced or dysfunctional[1]. Therapeutic strategies often aim to supplement or mimic these natural tear components using artificial tears enriched with similar molecules (e.g., hyaluronic acid/trehalose), secretagogues that stimulate endogenous secretion of tear factors (such as P2Y2 receptor agonists like diquafosol), or drugs that modulate immune responses on the ocular surface[4][6][8]. However, "anti-inflammatory effect via natural tear components" does **not correspond to a single molecular entity**—it is a functional description encompassing multiple molecules with overlapping roles in maintaining ocular health. Therefore: - It is not considered a canonical drug target such as an enzyme or receptor. - There are no standard abbreviations or aliases. Drugs used in this therapeutic area include cyclosporine A (Restasis), lifitegrast (Xiidra), corticosteroids like loteprednol etabonate (Eysuvis), secretagogues like diquafosol sodium eyedrops targeting P2Y2 receptors[4][7], and artificial tears containing mimetics of mucins/lipids/hyaluronic acid/trehalose[6][10]. Their mechanisms involve immunomodulation rather than direct action on "natural tear component(s)" per se. In summary: This entry describes a **therapeutic concept**, not an individual molecular target; thus it should be flagged as incorrect if used where a specific molecule/receptor is required.

Therapeutic strategies involve immunomodulation, stimulating endogenous secretion of tear factors, or supplementing tear components, rather than direct action on a single 'natural tear component'.